Navigation Links
GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

Aaron Whiteman, CEO for GENova says, "Following a rigorous evaluation phase, we have selected three potential blockbuster drug target patents for acquisition, and we look forward to integrating them into our IP portfolio." The acquisition targets still subject to due diligence and contract would include both preclinical and clinical drugs that show promising potential in the major markets of anti-cancer and anti-infective drugs.

GENova will announce details of these new biological products in the coming weeks.

GENova's Current IP Portfolio

The three new patents would join GENova's current proprietary IP products --tetanolic acid (for breast cancer) and prostaganin (for prostate cancer)-- in the company's growing IP portfolio.

Known as an alpha hydroxyoleic acid, tetanolic acid is a form of a lipid that has the demonstrated ability to affect the growth and proliferation of cells. Seeing that cancer is characterised as a normal proliferation of cells, these lipids can potentially prevent cancer spread. Preliminary tests in mice have shown that the protein can prevent the growth and spread of cancer in mice. GENova's Tetanolic acid is therefore a prime candidate for development of an anti-cancer medicament in humans. The breast cancer therapeutics market is expected to grow from its current level of US$5.9 billion (EUR5 million) to $11.5 billion by 2011, with a compound annual growth rate (CAGR) of 9.8 per cent (Frost Sullivan).

GENova's proprietary peptide for prostate cancer, Prostaganin, de
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova files patent for new breast cancer treatment
2. GENova appoints Director of Asian business development
3. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. Genova files patent for new prostate cancer treatment
6. GENova names Dr. John Savin as Vice President
7. GENova names Aaron Whiteman as CEO
8. Kapstone Medical Acquires Exclusive License to New Orthopedic Technology
9. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A.
10. Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
11. Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , ... July 28, 2015 , ... ... SmileCareClub Invisible Aligner System to its online product offerings, giving its ... a teledentistry model and cloud-based technology, SmileCareClub allows patients to get quality, remote ...
(Date:7/28/2015)... ... ... Women fear developing Alzheimer's disease more than having a heart attack or stroke ... but there is little an individual can do to arrest the progress of Alzheimer's ... reports the July 2015 Harvard Women's Health Watch . , "There are now ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... (ACS-Heart Attack, Sudden Death, or Angina), many of whom are missed by conventional ... of individuals with active yet undetected sub-clinical disease, who are at risk of ...
(Date:7/28/2015)... ... July 28, 2015 , ... For more than ... has based its selection process on the foundation of peer nominations. Physicians nominate ... in any area of medicine and in any part of the country. Physicians ...
(Date:7/28/2015)... Miami, FL (PRWEB) , ... July 28, 2015 ... ... according to a number of publications, including Runner’s World Magazine, is plantar ... remedy this constant pain. , Designed by a professional athletic trainer, the ...
Breaking Medicine News(10 mins):Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2
... Calif., July 2 SuperGen, Inc.,(Nasdaq: SUPG ... rapid,development and commercialization of therapies for solid tumors ... Ph.D.,President and Chief Executive Officer, is scheduled to ... July 9, 2008 at the,Mandarin Oriental Hotel in ...
... Display Paintings at Grumpy,s Cafe; Works on Sale ... Shore Hospital,s Festival of the Arts, CLEVELAND, July 2 ... Home Art Program is now on display at Grumpy,s,Cafe, 2621 ... The exhibition includes several paintings from residents of Joseph,s,Home, a ...
... SXC Health Solutions Corp.,("SXC" or the "Company") ... leading provider of,technology and pharmacy benefits management ... informedRx suite of services with The University,of ... renewal include: RxCLAIM(R),for on-line adjudication services of ...
... supporting Lactation, Consultants, Midwives, Doulas, and Childbirth Educators, giving them ... and expand their, practices by connecting with the 2 million ... ... BOULDER, Colo., July 2 Breastfeeding.com, a premier,online resource with ...
... most powerful anti-inflammatory system, controlling digestion, detoxification, glucose metabolism as well ... nourish the cell membranes of neurons for unprecedented results in fighting ... improving energy, immune and brain function*. , ... Los ...
... should understand and consider the economic impact of new ... report appearing in the July/August issue of CA: ... of the American Cancer Society. The report says health ... to be aware of the relative costs and benefits ...
Cached Medicine News:Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:Artwork by Homeless Men on Display in Tremont Cafe 2Health News:Artwork by Homeless Men on Display in Tremont Cafe 3Health News:SXC Health Solutions announces informedRx renewal contract with The University of Michigan 2Health News:Breastfeeding.com Launches First Ever Social Network for Birth-Related Medical Professionals 2Health News:Breakthrough "Neuro Nutrition" Targets the Brain and Vagus Nerve To Boost the Body's Immune, Hormone and Neurological Systems 2Health News:Breakthrough "Neuro Nutrition" Targets the Brain and Vagus Nerve To Boost the Body's Immune, Hormone and Neurological Systems 3Health News:Breakthrough "Neuro Nutrition" Targets the Brain and Vagus Nerve To Boost the Body's Immune, Hormone and Neurological Systems 4Health News:Breakthrough "Neuro Nutrition" Targets the Brain and Vagus Nerve To Boost the Body's Immune, Hormone and Neurological Systems 5Health News:Report says clinicians should consider economic impact of new interventions 2
(Date:7/28/2015)... 2015 Baebies, Inc. today announced the completion ... The oversubscribed round of financing included key investors Rex ... Cunning Capital, Triad, LLC, the Duke Angel Network and ... of Advanced Liquid Logic,s (ALL) former investors including Charleston ... "Rex is pleased to support this promising ...
(Date:7/28/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, announced ... after the market closes on Tuesday, August 4, 2015. ... the same day at 4:30 p.m. ET (1:30 p.m. ... corporate update. The live call may be ...
(Date:7/28/2015)... Oncology, Inc. (OTC: CSBR), engaged in the development of ... and use of oncology drugs, today announced its financial ... Fourth Quarter and Recent Business Highlights: , ... period result , Procured a quarterly record high ... Champions Oncology CEO, stated, "The end of fiscal 2015 ...
Breaking Medicine Technology:Baebies, Inc. Raises $13 Million in Oversubscribed Round of Financing 2Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11
... MISSISSAUGA, Ontario, Aug. 23, 2011 Valeant Pharmaceuticals International, ... has filed a Notice of Intention to make a ... (the "TSX") and that the TSX has accepted the ... have the right to purchase for cancellation, commencing August ...
... BOSTON, Aug. 23, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... will result in the reduction of more than $620,000 in ... settlement agreement and new consulting agreement will result in a ... Solos Endoscopy posted its financial statements for period ended June ...
Cached Medicine Technology:Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 2Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 3Solos Endoscopy to Reduce Debt by Over $620,000 2